Markers of early cardiotoxicity in patients with breast cancer undergoing chemotherapy depending on blood pressure level

Saidova, M. A.; Ашотовна, Авалян Ани; Kirillova, M.; Юрьевна, Кириллова Мария; Шитов, В Н; Николаевич, Шитов Виктор; Oshchepkova, Ye V; Владимировна, Ощепкова Елена; Саидова, М. А.; Абдулатиповна, Саидова Марина; Стенина, М. Б.; Борисовна, Стенина Марина; Chazova, I.; Евгеньевна, Чазова Ирина

doi:10.26442/2075-082x_14.3.21-27

Cited by 5 publications

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Кроме этого, в последние годы для ранней диагностики антрациклин-индуцированного повреждения сердца и прогнозирования клинического течения токсической сердечной недостаточности широко изучается применение тканевого допплеровского эхокардиографического исследования. Определение величины и скорости деформации миокарда левого желудочка по данным литературы характеризуются более высокой чувствительностью по сравнению с оценкой динамики ФВ ЛЖ [11].…”

Section: сибирский журнал клинической и экспериментальной медициныunclassified

Review of potential predictors of anthracycline-induced cardiotoxicity from the position of disease pathogenesis

Кужелева

Garganeeva

Тукиш

et al. 2022

SJCEM

View full text Add to dashboard Cite

Cardiotoxicity of anthracycline chemotherapy drugs is one of the main interdisciplinary problems in the research area of cardio-oncology. As is known, the high antitumor effi cacy of anthracycline antibiotics is signifi cantly leveled by the development of disabling and lethal heart lesions. However, the pathogenesis of toxic heart disease, as well as diagnostic criteria and markers of anthracycline-induced cardiomyopathy are not fully understood. The article provides a detailed review of potential markers of anthracycline cardiotoxicity from the position of disease pathogenesis. The scheme of pathogenetic development of anthracycline-induced cardiomyopathy is proposed in this article. The main methods of diagnostics of toxic damage of the heart that are currently used in clinical researches of domestic and foreign scientists are reviewed.

show abstract

Section: сибирский журнал клинической и экспериментальной медициныunclassified

Review of potential predictors of anthracycline-induced cardiotoxicity from the position of disease pathogenesis

Кужелева

Garganeeva

Тукиш

et al. 2022

SJCEM

View full text Add to dashboard Cite

show abstract

Evaluation of subclinical cardiotoxicity in patients with breast cancer and arterial hypertension in two regimens of anthracycline-containing chemotherapy

et al. 2018

View full text Add to dashboard Cite

Objective. To study of subclinical cardiotoxicity of two anthracycline-containing chemotherapy regimens in breast cancer patients with normotension and arterial hypertension. Materials and methods. 119 women (mean age 48,8±10,9 years) with triple negative breast cancer were enrolled. They are received one of two chemotherapy options that differed in the intensity and duration of treatment, including the total dose of anthracyclines. Depending on the chemotherapy option, the patients were divided into two groups: group 1 (n=54) - treatment duration ≤8 weeks, cumulative dose of doxorubicin was 200 mg/m2, group 2 (n=65) - treatment duration ≤16 weeks, the cumulative dose of doxorubicin was 320 mg/m2. Before and after chemotherapy completion of all patients, the level of troponin T (h.s.) and NT-proBNP was determined, and heart ultrasound was performed, 2D and 3D speckle tracking imaging. Results. In patients who received a higher cumulative dose of doxorubicin (group 2), a statistically significant increase in biomarkers of myocardial damage was observed (h.s. troponin T before chemotherapy was 7.8±0.5 pg/ml, after chemotherapy - 55.0±7.0 pg/ml, p

show abstract

Modern Approaches to Detecting Early Subclinical Cardiotoxicity Induced by Chemotherapy in Patients With Breast Cancer

Avalyan,

Saidova,

Oshchepkova

et al. 2018

Evrazijskij kardiologičeskij žurnal

View full text Add to dashboard Cite

In recent decades, developed countries of the world have made progress in the treatment of breast cancer, both because of the early detection of cancer and the use of modern methods of treatment (target therapy and chemotherapy, radiation therapy and surgical treatment). Due to this, the time of disease-free course of cancer and the duration of life of patients have increased. However, a number of antitumor drugs have cardiotoxicity [1]. It is shown that cardiovascular diseases are the second leading cause of death among women who have undergone breast cancer [27]. Reduction of systolic function of the heart is the most common manifestation of cardiotoxicity of antitumor therapy [7]. Other manifestations of cardiotoxicity include arterial hypertension (AH), acute coronary syndrome, arrhythmias and thromboses. In recent years, methods such as electrocardiography (ECG); echocardiography (EchoCG) with the classical definition of the left ventricular ejection fraction (LVEF) by the method of Simpson's biplane and the global longitudinal strain of the left ventricular (GLS) using data from the 2D Speckle Tracking Imaging; determination of the level of biomarkers of myocardial damage and magnetic resonance imaging (MRI) of the heart have been used to detect the cardiotoxicity of antitumor therapy. Thus, the early diagnosis and timely detection of cardiotoxic effects of antitumor drugs are among the tasks of cardiooncology - an area in medicine formed in recent years [1].

show abstract

Markers of early cardiotoxicity in patients with breast cancer undergoing chemotherapy depending on blood pressure level

Cited by 5 publications

References 17 publications

Review of potential predictors of anthracycline-induced cardiotoxicity from the position of disease pathogenesis

Review of potential predictors of anthracycline-induced cardiotoxicity from the position of disease pathogenesis

Evaluation of subclinical cardiotoxicity in patients with breast cancer and arterial hypertension in two regimens of anthracycline-containing chemotherapy

Modern Approaches to Detecting Early Subclinical Cardiotoxicity Induced by Chemotherapy in Patients With Breast Cancer

Contact Info

Product

Resources

About